Correction to: The European Journal of Health Economics 10.1007/s10198-019-01101-x
In the published article, the Table 1 was published incorrectly.
The correct Table 1 is given below
| Variables | FF/VI 184/22 mcg and 92/22 mcg |
UC group |
|---|---|---|
| Monthly drug costs [17, 21] | €51.52a |
ICS = €18.75b ICS/LABA = €48.25b |
| Annual drug costs (€, 2018) | €627.26 | €557.31 |
| Asthma management direct annual costs (€, 2018)c [19, 20] | ||
| Uncontrolled (ACT score ≤ 15) | €1919.01 | |
| Partially controlled (ACT score 16–19) | €1015.61 | |
| Well-controlled (ACT score ≥ 20) | €656.90 | |
| Assumed proportion of days covered, % | 100 | 100 |
| Assumed current uptake, % | 10 | 90 |
| Assumed new uptake, % | 20 | 80 |
| Percentage of subjects in each ACT category (ITT population, n = 4233) [18] | ||
| Baseline | ||
| Uncontrolled | 41% | 41% |
| Partially controlled | 31% | 31% |
| Well-controlled | 28% | 28% |
| 24 weeks | ||
| Uncontrolled | 20% | 29% |
| Partially controlled | 20% | 25% |
| Well-controlled | 60% | 46% |
| 52 weeks | ||
| Uncontrolled | 21% | 30% |
| Partially controlled | 20% | 26% |
| Well-controlled | 59% | 44% |
FF/VI fluticasone furoate/vilanterol, ICS inhaled corticosteroid, ICS/LABA inhaled corticosteroid/long-acting beta-agonist, ACT Asthma Control Test, ITT intention-to-treat
aPrice to Public plus VAT of FF/VI 184/22 and 92/22 mcg
bUC cost calculated as a weighted average drug cost of all available presentations at Price to Public plus VAT
cCosts annualised at updated to 2018